Loading data for RAPP — first visit, this takes a few seconds.
Rapport Therapeutics Inc. (RAPP)
NasdaqGM: RAPP
· Real-Time Price · USD
49.07
+0.06 (0.12%)
At close: Aug 19, 2026, 3:59 PM
49.07
+0.00%
After-hours: 7:30 PM
Rapport Therapeutics Inc. (RAPP) Stock Price, Analysis & Data
0.12% (1D)
| Bid | n/a |
| Market Cap | 2.35B |
| Revenue (ttm) | 20M |
| Net Income (ttm) | -137.16M |
| Beta | 0.97 |
| EPS (ttm) | -3.03 |
| PE Ratio (ttm) | n/a |
| Forward PE | -9.38 |
| P/B (ttm) | 5.56 |
| P/S (ttm) | 117.71 |
| Earnings Date | Nov 5, 2026 |
| Ask | n/a |
| Volume | 228,943 |
| Avg. Volume (20D) | 353,941 |
| Open | 49.58 |
| Previous Close | 49.01 |
| Day's Range | 48.68 - 49.90 |
| 52-Week Range | 13.90 - 49.90 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About RAPP
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 7, 2024
Employees 84
Stock Exchange NasdaqGM
Ticker Symbol RAPP
Website https://www.rapportrx.com
Financial Performance
In 2025, Rapport Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -111.48M, an increase of 42.37%.
Financial StatementsEarnings Surprise
Rapport Therapeutics has released their quarterly earnings on Aug 5, 2026:
Rapport Therapeutics Inc. is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2